Collectively, current evidence suggests that while renin inhibitors may serve as an alternative for patients intolerant to ACEi/ARB, they do not demonstrate clear superiority, and their role may be more relevant in specific subgroups such as obesity-related hypertension or advanced microalbuminuria. The gene discussed is REN; the disease is obesity disorder.